Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Catherine J. Wu(Dana-Farber Cancer Institute), Taha Merghoub(Cornell University), Donna Neuberg(Otsuka (Japan)), Bastian Schilling(Goethe University Frankfurt), Kendell Clement(Broad Institute), Gëorge F. Murphy(Brigham and Women's Hospital), Zachary Cartun(Dana-Farber Cancer Institute), Diana Miao(Broad Institute), Patrick Ryan Potts(Amgen (United States)), Alexander Meissner(Max Planck Institute for Molecular Genetics), Andreas Gnirke(Broad Institute), Dirk Schadendorf(National Center for Tumor Diseases), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Arman W. Mohammad(Broad Institute), Jeffrey S. Weber(NYU Langone Health), Nir Hacohen(Cambridge Hospital), Clyde Bango(Harvard University), Jedd D. Wolchok(Cornell University), Levi A. Garraway(Broad Institute), Pavan Bachireddy(Broad Institute), Alexandra Snyder(MedStar Washington Hospital Center), Christina Galonska(Max Planck Institute for Molecular Genetics), Ying Huang(Mianyang Third People's Hospital), Mehrtash Babadi(Broad Institute), F. Stephen Hodi(Harvard University), Christine G. Lian(Brigham and Women's Hospital), Rupert Langer(Johannes Kepler University of Linz), Patrick Lee(Harvard University), Derin B. Keskin(Dana-Farber Cancer Institute), Qian Zhan(Brigham and Women's Hospital), Daniel Gusenleitner
Cited by 174
Related Papers
Full-length transcriptome assembly from RNA-Seq data without a reference genome
|Nature Biotechnology|2011|22.7k
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Comprehensive Mapping of Long-Range Interactions Reveals Folding Principles of the Human Genome
|Science|2009|9.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k